Eyal C. Attar is CHIEF MEDICAL OFFICER at Vor Biopharma Inc. (VOR). They have made 3 open-market trades across 1 company since 2019, most recently 2025-02-13.
CIK 0001789076
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $3K since 2019, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VOR | SELL · 10b5-1 | 2025-02-13 | 2025-02-18 | $1.42 | $3K | -23.9% | -40.0% | -87.6% |
| VOR | SELL · 10b5-1 | 2025-02-10 | 2025-02-12 | $1.37 | $3K | -11.3% | -36.9% | -88.7% |
| VOR | SELL · 10b5-1 | 2024-12-27 | 2024-12-31 | $1.25 | $13K | +19.6% | +24.1% | -35.9% |
| VOR | SELL · 10b5-1 | 2024-06-03 | 2024-06-04 | $1.39 | $20K | -13.5% | -31.7% | -37.3% |
| APRE | SELL | 2022-02-28 | 2022-03-01 | $1.73 | $62K | -0.6% | +6.9% | -51.9% |
| APRE | SELL | 2021-09-16 | 2021-09-20 | $4.68 | $149K | +3.4% | +3.8% | -34.0% |
| APRE | BUY | 2019-10-07 | 2019-10-07 | $15.00 | $3K | +1.4% | +23.8% | +111.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.